Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab

Abstract The impact of statins on patients receiving immune checkpoint inhibitors for advanced hepatocellular carcinoma (aHCC) remains unclear. This study aimed to evaluate whether statins influence overall survival (OS) and progression-free survival (PFS) in aHCC patients receiving Atezolizumab + B...

Descrición completa

Detalles Bibliográficos

Principais autores:	Andrea Dalbeni, Filippo Cattazzo, Marco Vicardi, Eugenio Franceschini, Claudia Campani, Giuseppe Cabibbo, Caterina Vivaldi, Andrea Palloni, Tiziana Pressiani, Massimo Iavarone, Alessandra Auriemma, Leonardo A. Natola, Piera Federico, Francesca Romana Ponziani, Gianluca Svegliati-Baroni, Benedetta Stefanini, Caterina Soldà, Francesco Giuseppe Foschi, Stefania De Lorenzo, Ingrid Garajova, Fabio Marra, Ciro Celsa, Gianluca Masi, Giovanni Brandi, Lorenza Rimassa, Mariangela Bruccoleri, Bruno Daniele, Leonardo Stella, Maria Ricci, David Sacerdoti, Francesco Tovoli, ARTE Study Group
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2025-11-01
Series:	Scientific Reports
Assuntos:	Hepatocellular carcinoma Metabolic dysfunction-associated steatotic liver disease Statins Immune-checkpoint inhibitors
Acceso en liña:	https://doi.org/10.1038/s41598-025-25752-4
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!